

This abstract was submitted to the DTRF Research Workshop in September, 2021.

AL102, Investigational Oral Gamma-Secretase Inhibitor for the Potential Treatment of Desmoid Tumors

Gary Gordon, MD, CMO and Jason Kaplan, MD, Medical Director, Ayala Pharmaceuticals

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for patients suffering from rare and aggressive cancers and other neoplasms. Our development approach is predicated on identifying and addressing tumorigenic drivers of cancer. Our current portfolio of product candidates targets the aberrant activation of the Notch pathway with Gamma Secretase Inhibitors (GSI).

AL102, a potent, selective, and oral GSI was originally developed by BMS and licensed by Ayala. It is being developed for the treatment of patients with desmoid tumors. Separately, it is developed in combination with Novartis' B-cell maturation antigen (BCMA)-targeting agents for the treatment of multiple myeloma. Here, we will present and discuss our ongoing pivotal Phase 2/3 **Research in GSIs for Desmoid Tumors (RINGSIDE)** trial for the treatment of adults and adolescents with progressing desmoid tumors.

Part A of RINGSIDE is open label and is enrolling up to 36 patients randomized among three dosing regimen arms: 1.2 mg daily (QD), 2 mg twice weekly (QIW), and 4mg twice weekly (QIW) with initial follow up of safety, tolerability and tumor volume by MRI after 16 weeks in order to determine the optimal dose. The study will also be closely assessing Quality of Life (QOL) measures by using Patient Reported Outcome (PRO) tools. At the end of Part A, all patients will be eligible to enroll into an open label extension study at the selected dose where long-term efficacy and safety will be monitored.

Part B of the study will start immediately after dose selection from Part A and will be a double-blind placebo-controlled study enrolling up to 156 patients with progressive disease, randomized 2:1 between AL102 or placebo. The study's primary endpoint will be progression free survival (PFS) with secondary endpoints including objective response rate (ORR), duration of response (DOR) and QOL measures derived from the GODDESS, PRO-CTCAE, TSQM-9, and Brief Pain Inventory PROs.

RINGSIDE is currently open for enrollment.